Currently, about 70 percent of new molecular entities exhibit poor solubility in water and require some form of enhancement in order to achieve sufficient bioavailability. However, the sheer number of potential strategies for improving the solubility of a compound can overwhelm many developers, leaving them unsure how to choose a path forward.
As the biopharmaceutical industry continues to evolve, the quality by design (QbD) holistic and proactive approach to drug development and manufacturing is transforming key processes. While QbD evolves from good practice to agency requirement, how can sponsors ensure that rigorous, scientific risk-based approaches are used to bring better and safer therapies to market faster?
Whether your company is built on a single molecule or you’re a global pharmaceutical leader, you need fast, cost-effective, and scientifically based insights during early-phase development. Leverage an innovative partner with proven expertise in early development to ensure quick problem solving, speed, and results.